IRCCS Azienda Ospedaliero Universitaria - Policlinico di Sant'Orsola

At IRCCS Azienda Ospedaliero Universitaria - Policlinico di Sant'Orsola in Bologna, clinical research in neoplasms and hematologic diseases focuses on major cancers and blood disorders, with studies aimed at testing new treatments and improving outcomes for patients with difficult-to-treat disease.

• Breast cancer research is evaluating new endocrine and targeted approaches for patients with advanced or early disease.
• Trials in acute myeloid leukemia, multiple myeloma, and myelodysplastic syndrome are assessing emerging therapies for relapsed or resistant blood cancers.
• Studies in chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-cell malignancies are exploring better treatment effectiveness and safety.
• Research on skin cancers is examining innovative cancer therapies for tumors that may be treated locally or in advanced settings.

This portfolio reflects a strong focus on both solid tumors and blood cancers, with an emphasis on therapies that may improve response, control recurrence, and support patients with advanced disease.

The site also supports trials in virus diseases, skin and connective tissue diseases, and bacterial infections and mycoses, covering conditions that range from inflammatory skin disorders to viral and fungal infections.

• Studies in atopic dermatitis are assessing new options to reduce symptoms and maintain treatment response.
• Research in ulcerative colitis and Crohn’s disease is evaluating therapies designed to improve remission and digestive health.
• Investigations in mpox virus disease are describing clinical outcomes and the potential role of antiviral treatment.
• Trials in onychomycosis are testing better treatments for fungal nail infection in children.

These studies aim to improve symptom control, support clinical remission, and expand treatment options across immune-mediated, infectious, and dermatologic conditions.

Clinical trials at the Policlinico di Sant'Orsola include work in digestive system diseases, male and female urogenital diseases, and not otherwise specified conditions, with a notable emphasis on kidney health and treatment optimization.

• Research in chronic kidney disease is evaluating biomarker-guided care to improve kidney function outcomes.
• Studies in end-stage kidney disease are exploring supportive approaches for patients starting dialysis.
• Trials in obesity or overweight are examining combined strategies that may help address both inflammatory disease activity and weight reduction.
• Additional work is focused on identifying whether tailored treatment decisions can better preserve renal function over time.

Overall, this area centers on kidney disease management and metabolic health, with the goal of making care more personalized and effective.